Allergan Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ALLERGAN, and when can generic versions of ALLERGAN drugs launch?
ALLERGAN has seventy-three approved drugs.
There are nine US patents protecting ALLERGAN drugs.
There are one hundred and eighty-one patent family members on ALLERGAN drugs in fifty-five countries and one hundred and sixteen supplementary protection certificates in eighteen countries.
Summary for Allergan
International Patents: | 181 |
US Patents: | 9 |
Tradenames: | 70 |
Ingredients: | 54 |
NDAs: | 73 |
Patent Litigation for Allergan: | See patent lawsuits for Allergan |
PTAB Cases with Allergan as patent owner: | See PTAB cases with Allergan as patent owner |
Drugs and US Patents for Allergan
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Allergan | AVYCAZ | avibactam sodium; ceftazidime | POWDER;INTRAVENOUS | 206494-001 | Feb 25, 2015 | RX | Yes | Yes | 7,112,592 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Allergan | AVAGE | tazarotene | CREAM;TOPICAL | 021184-003 | Sep 30, 2002 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Allergan | FIORINAL | aspirin; butalbital; caffeine | CAPSULE;ORAL | 017534-005 | Apr 16, 1986 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Allergan | BYSTOLIC | nebivolol hydrochloride | TABLET;ORAL | 021742-004 | Dec 17, 2007 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Allergan
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Allergan | BYSTOLIC | nebivolol hydrochloride | TABLET;ORAL | 021742-004 | Dec 17, 2007 | 6,545,040 | ⤷ Try a Trial |
Allergan | GELNIQUE 3% | oxybutynin | GEL, METERED;TRANSDERMAL | 202513-001 | Dec 7, 2011 | 7,029,694 | ⤷ Try a Trial |
Allergan | PROPINE | dipivefrin hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 018239-001 | Approved Prior to Jan 1, 1982 | 3,839,584 | ⤷ Try a Trial |
Allergan | OPTICROM | cromolyn sodium | SOLUTION/DROPS;OPHTHALMIC | 018155-001 | Oct 3, 1984 | 3,777,033 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for ALLERGAN drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Capsules | 4 mg and 8 mg | ➤ Subscribe | 2012-10-09 |
➤ Subscribe | Ophthalmic Solution | 0.05% | ➤ Subscribe | 2008-10-14 |
➤ Subscribe | Tablets | 5 mg and 10 mg | ➤ Subscribe | 2007-10-16 |
➤ Subscribe | Sublingual Tablets | 5 mg and 10 mg | ➤ Subscribe | 2013-08-13 |
➤ Subscribe | Extended-release Capsules | 60 mg | ➤ Subscribe | 2009-03-02 |
➤ Subscribe | Transdermal System Extended-re | 3.9 mg/24 hrs | ➤ Subscribe | 2008-08-19 |
➤ Subscribe | Ophthalmic Solution | 0.30% | ➤ Subscribe | 2007-07-19 |
➤ Subscribe | Tablets | 2.5 mg, 5 mg, 10 mg, and 20 mg | ➤ Subscribe | 2011-12-19 |
➤ Subscribe | Sublingual Tablets | 2.5 mg | ➤ Subscribe | 2017-07-27 |
International Patents for Allergan Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Hong Kong | 1196615 | ⤷ Try a Trial |
Montenegro | 00060 | ⤷ Try a Trial |
Poland | 3269717 | ⤷ Try a Trial |
World Intellectual Property Organization (WIPO) | 2011042560 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Allergan Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0771217 | 07C0001 | France | ⤷ Try a Trial | PRODUCT NAME: ETHINYLESTRADIOL BETADEX CLATHRATE; NAT. REGISTRATION NO/DATE: NL 32343 20060710; FIRST REGISTRATION: NL - RVG 31781 20050804 |
1214076 | C01214076/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: DROSPIRENONE + ETHINYLESTRADIOL; REGISTRATION NUMBER/DATE: SWISSMEDIC 57946 13.06.2008 |
0398460 | C300221 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: DROSPIRENON EN ETHINYLESTRADIOL; REGISTRATION NO/DATE: RVG 23827 20000307 |
1480644 | 93338 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: MELANGE OU ASSOCIATION PHARMACEUTIQUE COMPRENANT COMME INGREDIENTS ACTIFS : (1) CEFTAZIDIME OU UN SEL DE CELUI-CI ET (2) AVIBACTAM OU UN SEL DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/16/1109 - ZAVICEFTA - CEFTAZIDIME/AVIBACTAM |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.